News Release

For Immediate Release

BioCurex Presents Positive Results At International Oncology and Biomarkers Congress With Its RECAF(TM) Cancer Marker.

RICHMOND, British Columbia, Sept. 29, 2009 (GLOBE NEWSWIRE) -- Whispering Oaks International, Inc., d/b/a Biocurex (OTCBB:BOCX - News), announced today that it is making two presentations at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) being held this week in Amsterdam, The Netherlands. BioCurex's presentations address its RECAF cancer market test in combination with other currently used cancer markers: CA-125 for ovarian cancer and CEA for colorectal cancer.

The company's data show that combining RECAF with CA-125 detected 83% of ovarian cancers and combining RECAF with CEA detected 92% of colorectal cancers, with no false positives in either study. False positives are the most common reasons that most cancer marker tests are not useful for general screening. By combing the results of RECAF with these other cancer markers, the false positive rate was completely eliminated.

In addition, when the method was applied to very early stages of ovarian cancer, where a very high percentage of patients can be treated effectively, the combination test was still able to detect 75% of the cancer cases.

Dr. Moro, the Company's Chief Executive Officer, stated: "This is an important step ahead because CA-125 and CEA have been around for decades and combining them with RECAF provides a solution to the main problem with screenings: namely eliminating false positives while still detecting cancer cases at a high rate."

For more information on cancer markers, visit:

http://www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers

http://www.cancer.net/portal/site/patient/menuitem.169f5d85214941ccfd748f68ee37a01d/?vgnextoid=5662e195df06e010VgnVCM100000ed730ad1RCRD

For information about the ISOBM visit www.isobm.org.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see:  http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt).

The cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about the Company, please visit the News section in our web site (www.biocurex.com).

Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are “forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
Contact:
Ricardo Moro
BioCurex, Inc.
Tel: (604) 207-9150